Skip to main content

Table 2 Univariate and multivariate analyses in patients treated with chemotherapy

From: High expression of miR-25 predicts favorable chemotherapy outcome in patients with acute myeloid leukemia

Variables

EFS

OS

HR (95% CI)

P-value

HR (95% CI)

P-value

Univariate analyses

 MiR-25 (high vs low)

0.598 (0.376–0.951)

0.030

0.556 (0.347–0.890)

0.015

 WBC (< 20 vs ≥ 20 × 109/L)

0.939 (0.594–1.484)

0.786

0.936 (0.591–1.484)

0.779

 FLT3-ITD (positive vs negative)

1.242 (0.693–2.224)

0.467

1.192 (0.665–2.136)

0.555

 NPM1 (mutated vs wild)

1.168 (0.721–1.893)

0.527

1.044 (0.640–1.704)

0.862

 DNMT3A (mutated vs wild)

1.491 (0.909–2.446)

0.114

1.432 (0.868–2.362)

0.160

 RUNX1 (mutated vs wild)

1.464 (0.700–3.064)

0.312

1.591 (0.759–3.335)

0.219

 ITDH1 (mutated vs wild)

1.043 (0.452–2.405)

0.922

0.908 (0.366–2.254)

0.836

 ITDH2 (mutated vs wild)

0.981 (0.487–1.977)

0.956

0.991 (0.492–1.995)

0.979

Multivariate analyses

 MiR-25 (high vs low)

0.561 (0.333–0.943)

0.029

0.502 (0.296–0.851)

0.011

 WBC (< 20 vs ≥ 20 × 109/L)

0.884 (0.537–1.456)

0.629

0.927 (0.563–1.527)

0.766

 FLT3-ITD (positive vs negative)

1.489 (0.778–2.848)

0.229

1.578 (0.815–3.054)

0.176

 NPM1 (mutated vs wild)

0.877 (0.476–1.615)

0.674

0.760 (0.411–1.405)

0.382

 DNMT3A (mutated vs wild)

1.421 (0.787–2.568)

0.244

1.416 (0.787–2.550)

0.246

 RUNX1 (mutated vs wild)

1.730 (0.768–3.897)

0.186

1.805 (0.805–4.050)

0.152

 ITDH1 (mutated vs wild)

1.141 (0.448–2.904)

0.782

1.074 (0.397–2.906)

0.889

 ITDH2 (mutated vs wild)

1.039 (0.480–2.251)

0.922

1.042 (0.483–2.248)

0.916

  1. EFS event-free survival, OS overall survival, WBC white blood cell